AA001
/ Shenzhen Zhiyuan Biomedical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 31, 2026
A Phase Ib, Randomized, Double-blind, Placebo-controlled, Dose-escalation Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of AA001 Monoclonal Antibody in Chinese Patients with Mild Alzheimer's Disease and Alzheimer's Disease-Related Mild Cognitive Impairment.
(ChiCTR)
- P1 | N=36 | Not yet recruiting | Sponsor: Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University
New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders
1 to 1
Of
1
Go to page
1